89bio, INC Form 4 insider transactions

RA Capital Management and its affiliated funds disposed of their holdings in 89bio, Inc. following its acquisition by Roche Holdings, Inc. for $14.50 cash plus a contingent value right.

Kathleen LaPorte's stock options in 89bio, Inc. were converted into cash and contingent value rights following the company's acquisition by Roche Holdings, Inc. for $14.50 per share plus CVRs.

89bio, Inc. director Michael R. Hayden disposed of all his common stock and stock options following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a contingent value right.

89bio's Chief Financial Officer, Ryan Martins, reported significant equity transactions, including RSU settlement and disposal of shares and options, as part of the company's acquisition by Roche Holdings.

89bio Director Steven Altschuler disposed of all his stock options as part of the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR.

89bio, Inc. CEO Rohan Palekar disposed of all his common stock and derivative securities following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR per share.

89bio Director Charles McWherter disposed of all his common stock and stock options following the completion of the merger with Roche Holdings, Inc. for $14.50 cash plus CVRs.

89bio Director Edward Atkinson III disposed of stock options as part of the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus CVRs.

Lota S. Zoth, a director at 89bio, Inc., disposed of stock options as part of the company's acquisition by Roche Holdings, Inc. on October 30, 2025.

89bio's Chief Technical Operations Officer, Quoc Le-Nguyen, reported the disposition of shares and options following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus CVRs.

89bio, Inc. Director Martin Babler's stock options were disposed of as part of the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR.

89bio Director Derek DiRocco disposed of stock options as part of the company's acquisition by Roche Holdings, Inc., receiving cash and contingent value rights.

89bio, Inc. Chief Operating Officer Sarena Francis Willard disposed of common stock and stock options following the completion of the company's merger with Roche Holdings, Inc.

89bio's Chief Medical Officer, Harry H. Mansbach, disposed of all his common stock and options following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR.

89bio's Chief Financial Officer, Ryan Martins, exercised stock options, increasing his direct beneficial ownership of common stock and correcting a prior administrative error.

An 89bio, Inc. officer had shares withheld from restricted stock unit vesting to cover tax obligations.

89bio's Chief Medical Officer, Harry H. Mansbach, disposed of 7,680 common shares valued at $9.16 per share to cover tax withholding obligations related to restricted stock unit vesting.

89bio's Chief Financial Officer, Ryan Martins, disposed of 7,680 common shares at $9.16 each to cover tax obligations related to restricted stock unit vesting.

89bio's Chief Operating Officer, Sarena Francis Willard, reported the sale of common stock to cover tax withholding obligations related to restricted stock unit vesting.

89bio CEO Rohan Palekar reported a disposition of 55,836 shares of common stock to cover tax obligations related to restricted stock unit vesting.

89bio, Inc.'s Chief Technical Operations Officer, Quoc Le-Nguyen, has filed a Form 4 indicating a planned sale of 10,461 shares of common stock on July 15, 2025, under a Rule 10b5-1 trading plan.

89bio, Inc.'s Chief Financial Officer, Ryan Martins, reported the disposal of 8,498 shares of common stock at $9.62 per share, primarily to cover tax withholding obligations related to restricted stock unit vesting.

Harry H. Mansbach, Chief Medical Officer of 89bio, Inc., reported the disposition of 8,498 shares of common stock at $9.62 per share to cover tax withholding obligations related to restricted stock unit vesting.

Quoc Le-Nguyen, Chief Technical Operations Officer of 89bio, Inc., reported the withholding of shares to cover tax obligations related to the vesting of restricted stock units.

Quoc Le-Nguyen, Chief Technical Operations Officer of 89bio, Inc., reported the sale of 15,329 shares of common stock on April 15, 2025, according to a Form 4 filing with the SEC.

Quoc Le-Nguyen, Chief Technical Operations Officer of 89bio, Inc., reports transactions involving common stock and stock options.

Rohan Palekar, CEO of 89bio, Inc., reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Ryan Martins, CFO of 89bio, Inc., reports a transaction involving common stock to cover tax obligations.

Chief Medical Officer Harry H. Mansbach reports disposition of 1,050 shares of 89bio, Inc. stock to cover tax obligations.

89bio CEO Rohan Palekar disposed of 8,946 shares of common stock on February 9, 2025, to cover tax withholding obligations related to vesting restricted stock units.